Gornitzky represented the underwriters, led by SVB Leerink and Stifel, in Compugen Ltd.’s USD 79 million follow-on offering of shares on the Nasdaq Global Market.
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The company’s shares are dually traded on Nasdaq and the Tel Aviv Stock Exchange.
SVB Leerink and Stifel, Nicolaus & Company acted as joint bookrunning managers for the offering. SunTrust Robinson Humphrey acted as lead manager for the offering and Oppenheimer & Co. acted as co-manager for the offering.
The underwriters were represented by partners Chaim Friedland and Ari Fried, along with associates Neta Peled, Sharon Reingwirtz and Astar Shechter.
